SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) announced that its collaborator MediLink released interim results from the randomized Phase III TAISHAN-302 trial evaluating Tam-Peli (tambotatug pelitecan, YL201) versus topotecan in Chinese patients with relapsed small-cell lung cancer (SCLC) who had progressed after prior platinum-based chemotherapy with or without a PD-L1 inhibitor.
The trial met its primary endpoint of overall survival (OS), with Tam-Peli reducing the risk of death by 54% compared to topotecan. Tam-Peli also demonstrated strong efficacy across secondary endpoints, reducing the risk of disease progression by 71% and achieving an objective response rate of 59.1% versus 9.7% with standard-of-care.
Following the positive Phase III TAISHAN-301 trial in nasopharyngeal carcinoma, TAISHAN-302 represents the second successful Phase III readout for Tam-Peli in China. Under Roche's collaboration and exclusive licensing agreement with MediLink Therapeutics, Roche holds development, manufacturing, and commercialization rights for Tam-Peli worldwide outside mainland China, Hong Kong, and Macau. Roche is advancing clinical development across multiple solid tumor types and plans to rapidly initiate global Phase III trials.
RHHBY closed Friday's regular trading at $52.75 down $0.44 or 0.83%.
For More Such Health News, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News
